Archives of Medical Research
Volume 40, Issue 6 , Pages 503-513 , August 2009

Cost-Effectiveness Analysis of a Quadrivalent Human Papilloma Virus Vaccine in Mexico

  • Luz Myriam Reynales-Shigematsu

      Affiliations

    • Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico
    • ,
  • Eliane R. Rodrigues

      Affiliations

    • Institute of Mathematics, Universidad Nacional Autonomous Mexico, Mexico, D.F., Mexico
    • ,
  • Eduardo Lazcano-Ponce

      Affiliations

    • Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico
    • Corresponding Author InformationAddress reprint requests to: Eduardo Lazcano-Ponce, Instituto Nacional de Salud Pública, Av. Universidad 655, 1er. Piso, Col. Santa María Ahuacatitlán, 62508 Cuernavaca, Morelos, México; Phone: (+52) (777) 3293003; FAX: (+52) (777) 3111148

Received 5 June 2009 ,Accepted 19 June 2009.

References 

  1. PAHO.WHO 2001. Cancer Prevention. A Brief Snapshot of the Situation: Cervical Cancer in Latin America and the Caribbean, 2001. http://www.paho.org/English/HCP/HCN/CCBriefSnapshot.htm (accessed June 2008).
  2. OPS. 2002. Cáncer del cuello del útero: creciente amenaza en las Américas. http://www.paho.org/Spanish/DPI/100/100feature06.htm (accessed June 2008).
  3. Lazcano-Ponce E, Palacio-Mejia LS, Allen-Leigh B, et al. Decreasing cervical cancer mortality in Mexico: effect of Papanicolaou coverage, birthrate, and the importance of diagnostic validity of cytology. Cancer Epidemiol Biomarkers Prev. 2008;17:2808–2817
  4. Palacio-Mejía LS, Lazcano-Ponce E, Allen-Leigh B, et al. Regional differences in breast and cervical cancer mortality in Mexico between 1979-2006. Salud Publica Mex. 2009;51(suppl 2):S208–S219
  5. SSA. Programa de Acción: Cáncer Cérvico-Uterino. Primera Edición; 2002.
  6. Munoz N, Castellsagué X, Berrington de González B, et al. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24S3:S3/1–S3/10
  7. Hernández-Ávila M, Lazcano-Ponce EC, Berumen-Campos J, et al. Human papilloma virus 16–18 infection and cervical cancer in Mexico: a case-control study. Arch Med Res. 1997;28:265–271
  8. Lazcano-Ponce E, Rojas-Martínez R, López-Acuña MP, et al. Factores de riesgo reproductivo y cáncer cervico-uterino en la Ciudad de México. Salud Pública Mex. 1993;35:65–73
  9. Harro CD, PangYY Roden RB. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93:284–292
  10. Schiller J, Lowy D. Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr. 2001;93(28):50
  11. Koustky LA, Aula KA, Wheeler CM, et al. A trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645–1651
  12. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–278
  13. Franco EL, Cuzick J, Hildesheim A, et al. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24S3:S3/171–S3/177
  14. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP. Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine. 2006;24S3:S3/155–S3/163
  15. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781–798
  16. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89:101–105
  17. Clifford G, Franceschi S, Diaz M, et al. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;24S3:S3/26–S3/34
  18. Lacey CJ, Lowndes CM, Shah K. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24S3:S3/35–S3/41
  19. Norma Oficial Mexicana NOM-014-SSA2-1994 para la prevención, detección, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer cérvico uterino; 1994.
  20. Drummond M, O'Brien B, Stoddart G, et al. Métodos para la Evaluación Económica de los Programas de Asistencia Sanitaria. Segunda Edición. Madrid: Ediciones Díaz de Santos; 2001;
  21. Evans DB, Edejer TT, Adam T, et al. Methods to assess the costs and health effects of interventions for improving health in developing countries. BMJ. 2005;331(7525):1137–1140
  22. WHO. Making choices in health. In:  Tan-Torres Edejer T,  Baltussen R,  Adam T,  Hutubessy R,  Acharya A,  Evans DB,  Murray CJL editor. WHO guide to cost-effectiveness analysis. Geneva: WHO; 2003;
  23. Muenning P. Designing and Conducting Cost-effectiveness Analyses in Medicine and Health Care. San Francisco: John Wiley & Sons; 2002;
  24. Burchell NA, Winer RL, de Sanjosé S, et al. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24S3:S3/52–S3/61
  25. Banco de Mexico. GDP Per cápita Mexico 2004.
  26. WHO (World Health Organization): WHO-CHOICE: World Health Organization statistical information system: CHOICE (CHOosing Interventions that are Cost Effective), April 21, 2006. www.who.int/whosis/en/. Disease Control Priorities Project.
  27. Vaccarella S, Franceschi S, Herrero R, et al. IARC HPV Prevalence Surveys Study Group. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev. 2006;15:326–333
  28. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  29. Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of human papillomavirus (HPV) infection and cervical cancer: potential impact of an HPV 16/18 vaccine. Int J Cancer. 2003;106:896–904
  30. Franco EL, Tsu V, Herrero R, et al. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Vaccine. 2008;26(suppl 11):L88–L95
  31. DeWilde S, Anderson R. Med Decis Making. 2004;24:486–492
  32. Garnett GP, Kim JJ, French K, et al. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 2006;24S3: S3/178–S3/186
  33. Insinga RP, Dasbach EJ, Elbasha EH, et al. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine. 2007;26:128–139
  34. Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med. 2006;3:e138
  35. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604–615
  36. Avila L, Cahuana L, Pérez R. Cuentas nacionales de salud reproductive y equidad de genero. Ciudad de Mexico/Cuernavaca, México: Secretaría de Salud/Instituto Nacional de Salud Pública; 2005;
  37. Myers E. Mathematical models as research tools for HPV disease. Papillomavirus Rep. 2002;13:141–144
  38. Lazcano-Ponce E, Herrero R, Munoz N, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer. 2001;91:412
  39. Lajous M, Mueller N, Cruz-Valdez A, et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev. 2005;14:1710–1716
  40. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economics impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev. 2006;28:88–100

PII: S0188-4409(09)00142-8

doi: 10.1016/j.arcmed.2009.08.004

Archives of Medical Research
Volume 40, Issue 6 , Pages 503-513 , August 2009

Article Tools

* Image Usage & Resolution